可溶性Klotho与血液透析患者心血管事件、骨折及死亡风险的关联
该多中心队列纳入1241例血液透析患者,中位随访39个月,可溶性Klotho中位浓度325.6 pg/ml。最低四分位组较高四分位组心血管事件、骨折及全因死亡风险均显著升高,提示低sKlotho与不良预后相关。
要点
- 低sKlotho水平与血透患者心血管事件风险升高相关(HR=1.76)。
- 低sKlotho水平与骨折风险升高相关(HR=1.99)。
- 低sKlotho水平与全因死亡风险升高相关(HR=1.74)。
核心结论
- 低血清sKlotho水平与血液透析患者心血管事件、骨折及全因死亡风险升高相关。
- sKlotho可能作为该高危人群风险分层的生物标志物。
研究设计与样本
- 多中心队列研究,纳入1241例血液透析患者,中位随访39个月。
主要发现
- 随访期间记录436例心血管事件、100例骨折事件和228例死亡。
- sKlotho最低四分位组较高四分位组心血管事件风险显著升高(HR=1.76;95%CI:1.20-2.60)。
- sKlotho最低四分位组较高四分位组骨折风险显著升高(HR=1.99;95%CI:1.01-3.91)。
- sKlotho最低四分位组较高四分位组全因死亡风险显著升高(HR=1.74;95%CI:1.00-3.03)。
关键数值与推荐
- sKlotho中位浓度为325.6 pg/ml(IQR:248.9-434.4 pg/ml)。
临床怎么用
- 可考虑检测血清sKlotho水平辅助识别血液透析患者中的高心血管、骨折及死亡风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Klotho, an aging-suppressor protein, has been shown to promote cardiovascular and bone health in animal models of chronic kidney disease (CKD). However, limited data exist on its role in clinical outcomes among patients undergoing hemodialysis. This study aimed to investigate the association between soluble Klotho (sKlotho) levels and cardiovascular disease (CVD) events, fractures, and all-cause mortality in this population. METHODS: We enrolled 1241 patients on hemodialysis from multiple medical institutions, with a median follow-up of 39 months. The primary outcome was a composite of CVD events, fractures, and all-cause mortality. RESULTS: The median sKlotho concentration was 325.6 pg/ml (interquartile range [IQR]: 248.9-434.4 pg/ml). During the follow-up, 436 CVD and 100 fracture events were recorded, along with 228 deaths. Patients in the lowest quartile of sKlotho had significantly higher risks of CVD events (hazard ratio [HR] = 1.76; 95% confidence interval [CI]: 1.20-2.60), fractures (HR = 1.99; 95% CI: 1.01-3.91) and mortality (HR = 1.74; 95% CI: 1.00-3.03) than those in the highest quartile. CONCLUSION: These findings suggest that low serum sKlotho levels are strongly associated with poor cardiovascular and skeletal outcomes and increased mortality in patients on hemodialysis. This study highlights the potential utility of sKlotho as a biomarker for risk stratification in this high-risk population.
引用
- Nakashima A, Kato K, Kobayashi A, et al. Klotho's Impact on Cardiovascular Disease, Fractures, and Mortality in Hemodialysis. Kidney Int Rep. 2025. PMID: 41141519. doi:10.1016/j.ekir.2025.07.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。